Verified Beauty Data

Ingredient dossier Nº 017 / The verified record

Peptides

PALMITOYL PENTAPEPTIDE-4 · multiple CosIng entries · also copper peptides, signal peptides, argireline, GHK-Cu

Effective concentration, the pH it needs, how the derivatives compare, stability in the bottle, and the open questions — every scientific claim on this page links to its source.

Editorial verdict / Social intelligence

Qualified yes Ingredient dossier

Real mechanisms, modest evidence — peptides are the skincare category where the science sounds better than the independent clinical proof actually is. 1

Beauty benefit
Cosmetic peptides are short amino acid chains marketed primarily for anti-aging: signal peptides (Matrixyl, Matrixyl 3000) claim to prompt fibroblasts to build collagen; carrier peptides (GHK-Cu) deliver copper ions to repair sites; neurotransmitter-inhibiting peptides (argireline) mimic botulinum toxin by interrupting muscle contraction at the neuromuscular junction. The mechanisms are biologically plausible. The practical reality is that most cosmetic peptides substantially exceed the 500 Dalton molecular weight threshold associated with passive skin penetration, and independent human clinical trial evidence is thin — the best evidence for any single peptide is one industry-affiliated split-face RCT at 3 ppm. Effects, where observed, are modest and slow.
Does it work
Qualified yes — with honest caveats. The best-evidenced peptide, palmitoyl pentapeptide-4 (Matrixyl), has one genuine double-blind split-face RCT showing significant wrinkle improvement over 12 weeks at 3 ppm versus vehicle — conducted by the ingredient's manufacturer. Argireline shows up to 30% periorbital wrinkle depth reduction at 10% in the originating inventor's study. GHK-Cu stimulates collagen synthesis in fibroblast cultures at picomolar concentrations but lacks controlled human topical RCT data. The fundamental unresolved issue: whether intact peptide molecules reach dermal fibroblasts in cosmetically meaningful amounts after traversing intact skin remains poorly established. A 2026 systematic review found peptides are safe and show modest benefit, but calls for larger independent RCTs. Other ingredients (retinol, vitamin C) have a substantially deeper clinical evidence base. See the science below →

Consensus strength

Mixed

Dermatologist and editorial consensus acknowledges that peptide mechanisms are plausible and that the class is safe, but consistently flags that clinical evidence is thin, industry-affiliated, or confined to in-vitro models. The penetration problem — most cosmetic peptides exceed 500 Da and are hydrophilic, making stratum corneum traversal thermodynamically unfavorable — is acknowledged in peer-reviewed literature (Bos & Meinardi 2000; Choi 2014; the 2025 AH-8 permeability review) and by informed editorial sources. No source calls peptides outright fraudulent; none calls them a gold standard. The consensus is: promising but underproven, safer than overhyped, worth using if affordable, not worth prioritising over retinol or vitamin C.

01 / What it does

What it does

Cosmetic peptides are short chains of amino acids — typically two to ten residues — used in skincare to signal, carry, or inhibit. The class divides into three functional groups: signal peptides (e.g., palmitoyl pentapeptide-4 / Matrixyl, palmitoyl tripeptide-1 and palmitoyl tripeptide-38 / Matrixyl Synthe'6) that mimic matrikine fragments to prompt fibroblasts to produce collagen and other extracellular matrix components; carrier peptides (notably copper tripeptide-1 / GHK-Cu) that chelate trace minerals and deliver them to sites of wound repair and remodelling; and neurotransmitter-inhibiting peptides (acetyl hexapeptide-8 / argireline) that compete with SNARE-complex proteins to reduce acetylcholine-driven muscle contraction, positioning them as topical 'botox-like' agents. The in-vitro and manufacturer-sponsored evidence for each class is substantial; independent, well-controlled topical RCT data in humans are more limited, effect sizes in clinical studies are modest, and the fundamental question — whether large, often hydrophilic peptide molecules penetrate intact stratum corneum in sufficient concentrations to reach dermal fibroblasts — remains incompletely resolved.

02 / Effective concentration

What percentage actually works

Effective range

varies by peptide

Signal peptides such as pal-KTTKS are formulated at very low concentrations (3–200 ppm) because they are expensive actives used in the ppm range. Neurotransmitter-inhibiting peptides such as argireline show effects in published studies at 5–10% concentrations, though many commercial products use lower amounts. Copper tripeptide-1 is typically used at trace levels (<1%). There is no universal effective-concentration window across the class — each peptide has distinct dose-response data, largely from in-vitro or manufacturer-sponsored studies.

The Robinson et al. (2005; PMID:18492182) split-face RCT used 3 ppm pal-KTTKS, which is the most clinically cited reference dose for that peptide. Blanes-Mira et al. (2002; PMID:18498523) used 10% argireline and observed up to 30% reduction in wrinkle depth by profilometry — this is a high-end cosmetic dose that most consumer formulations do not reach. Manufacturers often cite in-vitro EC50 data to justify lower concentrations in formulation, but translating in-vitro thresholds to topically applied doses is methodologically problematic. The key confound across all peptide concentration data is unknown dermal bioavailability after transdermal traversal.

  • Study In the Robinson 2005 RCT, 3 ppm palmitoyl pentapeptide-4 in a moisturiser base produced significant improvement in facial wrinkles over 12 weeks versus vehicle control in women aged 35–55. 1
  • Study Blanes-Mira et al. (2002) tested 10% argireline in an oil/water emulsion on healthy women volunteers and observed up to 30% reduction in wrinkle depth by skin topography analysis after 30 days. This is the originating manufacturer-affiliated study and the highest published cosmetic concentration for argireline. 2

One honest caveat The fundamental penetration question is unresolved: most cosmetic peptides substantially exceed the 500 Da molecular weight threshold associated with passive stratum corneum penetration, and direct measurement of intact peptide reaching dermal fibroblasts after cosmetic-dose topical application has not been demonstrated in published independent studies.

03 / pH requirement

The pH it needs

Target pH

pH 5.0–7.0 (broad tolerance)

Unlike L-ascorbic acid, cosmetic peptides do not require a strict low-pH formulation to penetrate the skin — ionisation state is not the primary barrier for most peptides. The critical formulation variables are: (1) molecular weight and size — the widely cited '500 Dalton rule' (Bos & Meinardi 2000; PMID:10839713) holds that molecules above 500 Da have negligible passive skin penetration; most cosmetic peptides substantially exceed this threshold. (2) Hydrophilicity — most signal and neurotransmitter-inhibiting peptides are hydrophilic, making traversal of the lipophilic stratum corneum energetically unfavourable. Palmitoylation (adding a C16 fatty acid tail) addresses this for signal peptides by increasing lipophilicity. (3) Enzymatic degradation — peptides are rapidly cleaved by skin-surface and dermal proteases. Pal-KTTKS showed rapid degradation in ex-vivo hairless mouse skin models and neither KTTKS nor pal-KTTKS was detectable in the receptor chamber in full-thickness permeation studies (PMID:25143811). Formulators can work at pH 5.0–6.5 to maintain peptide stability and skin compatibility, but pH is not a meaningful efficacy lever for this class the way it is for vitamin C.

  • Study The '500 Dalton rule' holds that virtually no contact allergens exceed 500 Da because larger molecules cannot traverse the stratum corneum by passive diffusion; this threshold has been widely adopted as a heuristic for transdermal permeability of cosmetic actives. 5
  • Study Neither KTTKS nor its palmitoylated derivative pal-KTTKS was detected in the receptor solution after full-thickness hairless mouse skin permeation studies; both peptides degraded rapidly in skin, though pal-KTTKS was more stable than the unmodified form. 6

04 / Derivative ladder

How the derivatives compare

Every derivative trades a measure of proven activity for stability or gentleness. Skin conversion is the question that matters — a more stable molecule only helps if your skin can turn it back into the active form.

  1. Palmitoyl Pentapeptide-4 (Matrixyl)

    PALMITOYL PENTAPEPTIDE-4

    The original Matrixyl peptide from Sederma. Matrikine fragment from type-I collagen alpha-2 chain, modified with a palmitoyl tail for lipophilicity. The best-evidenced signal peptide in terms of independent peer-reviewed clinical data: Robinson et al. (2005; PMID:18492182) is a genuine split-face RCT, though industry-affiliated. Molecular weight ~802 Da, substantially above the 500 Da penetration threshold, which makes the in-vivo efficacy observation at 3 ppm somewhat paradoxical — vehicle effects, superficial hydration, and surface optical changes cannot be fully ruled out.

    • Study A 12-week split-face, double-blind, placebo-controlled RCT (n = 93) found that pal-KTTKS at 3 ppm in a moisturiser base produced significant improvement in facial wrinkle severity scores versus vehicle, assessed by image analysis and expert grader. 1
    • Study In full-thickness hairless mouse skin permeation studies, pal-KTTKS was not detected in the receptor compartment, indicating that penetration to the dermis under passive diffusion conditions is not established. 6

  2. Palmitoyl Tripeptide-1 + Palmitoyl Tetrapeptide-7 (Matrixyl 3000)

    PALMITOYL TRIPEPTIDE-1 / PALMITOYL TETRAPEPTIDE-7

    Matrixyl 3000 pairs a palmitoylated collagen-mimicking tripeptide with a palmitoylated fragment of IGF-1. In vitro, the combination is reported to upregulate collagen I, IV, fibronectin, and hyaluronic acid. The CIR Expert Panel (2018; DOI:10.1177/1091581818807863) reviewed safety and found typical use concentrations below 10 ppm. The claimed synergy between the two peptides is based primarily on in-vitro and manufacturer data; independent head-to-head human RCTs comparing Matrixyl vs Matrixyl 3000 are not available in the peer-reviewed literature.

    • CIR Palmitoyl tripeptide-1, palmitoyl tetrapeptide-7, and their derivatives are used in cosmetics at concentrations typically below 10 ppm and were concluded to be safe by the CIR Expert Panel; the safety assessment reviewed acute, subchronic, and sensitisation data. 12

  3. Palmitoyl Tripeptide-38 (Matrixyl Synthe'6)

    PALMITOYL TRIPEPTIDE-38

    Claimed to stimulate six extracellular matrix components: collagen I, III, IV, fibronectin, laminin, and hyaluronic acid. One published clinical study combining palmitoyl tripeptide-38 at 5 ppm with 15% L-ascorbic acid and tocopheryl acetate in a serum showed significant reduction in skin roughness parameters at 56 days (PMID:33103342). Because the formulation also contained high-dose vitamin C, the contribution of the tripeptide alone cannot be separated from this published study. Manufacturer-only data predominates for this peptide.

    • Study A 56-day study of a serum containing 15% l-ascorbic acid, tocopheryl acetate, and 5 ppm palmitoyl tripeptide-38 showed 8–9% significant reduction in facial skin roughness parameters and improvements in skin isotropy, redness, and homogeneity, as assessed by Primos® profilometry. The multi-ingredient formulation means tripeptide-38 contribution cannot be isolated. 8

  4. Copper Tripeptide-1 / GHK-Cu

    COPPER TRIPEPTIDE-1

    GHK is an endogenous tripeptide isolated from human plasma that binds copper(II) with high affinity. It is thought to function physiologically in wound healing as a matrikine liberated by tissue proteases. In vitro, GHK-Cu stimulates fibroblast collagen synthesis at picomolar concentrations (PMID:3169264). It is the best-characterised carrier peptide and has a longer research history than synthetic signal peptides. Key caveats: fibroblast in-vitro evidence does not establish topical anti-aging efficacy in intact human skin; controlled topical RCT data on cosmetic GHK-Cu concentrations are limited. The carrier peptide mechanism — delivering copper ions to remodelling sites — is plausible but the argument that supplementing copper drives net collagen synthesis in copper-replete skin is unproven.

    • Study GHK-Cu (10⁻⁹ M) significantly stimulates collagen synthesis by fibroblasts in culture, with activity detectable between 10⁻¹² and 10⁻¹¹ M and independent of cell number changes. The tripeptide-copper complex appears to recapitulate a physiological wound-healing signal. 4

  5. Acetyl Hexapeptide-8 (Argireline)

    ACETYL HEXAPEPTIDE-8

    Argireline was designed to competitively inhibit SNARE complex formation by mimicking the N-terminus of SNAP-25, thereby reducing vesicular fusion and acetylcholine release at the neuromuscular junction. It is the prototypal 'botox-like' topical peptide. The originating study (Blanes-Mira 2002; PMID:18498523) showed up to 30% wrinkle reduction at 10% concentration and was conducted by the peptide's inventors. A subsequent randomised, placebo-controlled study in Chinese subjects (Wang 2013; PMID:23607739) found 48.9% subjective anti-wrinkle response versus 0% placebo at 4 weeks. A 2025 skin permeability review (PMID:40565185) concludes that AH-8's hydrophilic nature and size limit passive stratum corneum penetration, which raises the question of how much reaches neuromuscular junctions — the intended site of action. Effect at cosmetic doses and the degree of neuromuscular inhibition achievable topically remain contested.

    • Study Argireline (Ac-EEMQRR-NH2) inhibits SNARE complex formation by competing with intact SNAP-25 for binding to syntaxin-1a and VAMP2, reducing Ca2+-dependent neurotransmitter exocytosis. In 10% topical emulsion applied to periorbital skin, wrinkle depth was reduced up to 30% by profilometry at 30 days in a volunteer study. 2
    • Study In a randomised, placebo-controlled study (n = 60) of argireline applied twice daily to periorbital wrinkles for 4 weeks, the subjective total anti-wrinkle efficacy rate was 48.9% in the argireline group versus 0% for placebo; objective skin roughness parameters showed significant decrease versus baseline (p < 0.01). 3
    • Review Due to its hydrophilic nature and relatively large molecular size, acetyl hexapeptide-8 faces limited permeability through the lipophilic stratum corneum, making effective dermal delivery to neuromuscular junctions a recognised formulation challenge. 10

05 / Stability & storage

Stability in the bottle

Peptides are chemically more stable than L-ascorbic acid under normal cosmetic conditions — they do not undergo the same oxidative colour-change that signals active loss. However, enzymatic and hydrolytic instability is the relevant concern: peptide bonds are cleaved by proteases present on the skin surface and in the stratum corneum, and by endopeptidases in cosmetic raw materials. Palmitoylation improves enzymatic stability relative to unmodified peptides (PMID:25143811). GHK-Cu's copper chelation may also confer some stability. Argireline is reported to be relatively stable in emulsion at near-neutral pH. The practical implication is that peptide activity loss during shelf life is possible but is more likely to occur via protease activity at application than by in-bottle degradation — the in-bottle stability of most commercial peptides in well-formulated products is acceptable at mildly acidic pH (5.0–6.5) with appropriate preservation.

In practice Buy it in an opaque, airless, or amber container, store it cool and out of the light, and treat a colour shift toward orange or brown as the signal to replace it — the molecule is telling you it has already oxidised.

06 / How to use it

How to actually use Peptides

When
AM/PM — After watery layers, before creams.
Pairs well with
niacinamide, hyaluronic acid, ceramides.
Apply apart from
direct acids in the same layer (space them)(use one in the morning, the other at night — not “never together”)
What to look for
Look for named peptides (Matrixyl, copper peptides, argireline).
Heads-up
Gentle and supportive; evidence is real but modest — a helper, not a retinoid replacement.

Practical guidance for routine placement — not a substitute for a dermatologist’s advice for your skin.

07 / The database

Peptides: measured product rankings coming soon

Ranked by $ per gram of active — what the working ingredient actually costs you, not the sticker price. Rows we have reviewed in full link through; the rest are data points from the same crawl.

Buy The Ordinary on Amazon $19.90 Top-ranked pick · affiliate link

No measured products yet — this active's price-per-gram rankings will appear here as products are added.

In the meantime, see how to use Peptides and what to look for on a label .

Contains it, but doesn't disclose a percentage: The Ordinary The Ordinary Multi-Peptide + HA Serum (Buffet) ; The INKEY List The Inkey List Peptide Moisturizer

08 / Safety

Is it safe?

Reviewed by the Cosmetic Ingredient Review — safe as used

Safe as used — CIR Expert Panel 2018 Final Safety Assessment covers Tripeptide-1, Hexapeptide-12, their metal salts and fatty acyl derivatives (including copper tripeptide-1 and palmitoyl tripeptide-1), and Palmitoyl Tetrapeptide-7. Panel concluded these are safe in present practices of use and concentration in cosmetics, noting typical use concentrations below 10 ppm and negative sensitisation and irritation data. A separate CIR Technical Report specifically covers Acetyl Hexapeptide-8 and Acetyl Hexapeptide-8 Amide (published 2020/2021 Final Report). No systemic toxicity concerns at cosmetic doses.

Cosmetic peptides have a good safety record at the concentrations used in over-the-counter formulations. Sensitisation is not a recognised concern for this class. Because most signal and carrier peptides are used at sub-10 ppm, systemic exposure from topical application is negligible. Argireline at 5–10% is the highest-concentration peptide commonly used; no serious adverse events have been reported in clinical studies at these concentrations. The theoretical concern about long-term facial muscle hypotonia from repeated topical argireline use has not been substantiated in published studies. Peptides derived from endogenous sequences (GHK) are considered particularly low-risk.

  • CIR The CIR Expert Panel concluded that tripeptide-1, hexapeptide-12, their metal salts (including copper tripeptide-1) and fatty acyl derivatives (including palmitoyl tripeptide-1), and palmitoyl tetrapeptide-7 are safe as used in cosmetics; the Panel specifically noted low use concentrations (typically <10 ppm) and absence of sensitisation signals. 12

09 / The limits of the evidence

What we don't know yet

Most of what you read about this ingredient is stated with more certainty than the evidence earns. Here is exactly where the record thins out — so you can weigh the claims above for yourself.

  1. The fundamental penetration question is unresolved: most cosmetic peptides substantially exceed the 500 Da molecular weight threshold associated with passive stratum corneum penetration, and direct measurement of intact peptide reaching dermal fibroblasts after cosmetic-dose topical application has not been demonstrated in published independent studies.
  2. The pivotal palmitoyl pentapeptide-4 RCT (Robinson 2005; PMID:18492182) was conducted by Procter & Gamble researchers using the company's own ingredient. No fully independent replication of this result in a separate population has been published.
  3. Virtually all GHK-Cu evidence for collagen stimulation comes from cell culture (PMID:3169264) and animal wound healing models. Controlled human topical RCT data on cosmetic GHK-Cu formulations is extremely limited in the independent peer-reviewed literature.
  4. Argireline's neurotransmitter-inhibiting mechanism requires the peptide to reach the neuromuscular junction. The degree to which this occurs after topical cosmetic application has not been directly measured; the 'up to 30% wrinkle reduction' figure from Blanes-Mira (2002; PMID:18498523) comes from the peptide's inventors, and the wrinkle measurement methodology is not independently validated.
  5. Most clinical studies on cosmetic peptides use multi-ingredient formulations, making it impossible to attribute observed effects to the peptide alone rather than to moisturisation, humectants, emollients, or antioxidants in the base.
  6. The palmitoyl tripeptide-38 / Matrixyl Synthe'6 evidence is predominantly manufacturer-sponsored and in vitro. The available published clinical study (PMID:33103342) combined it with 15% L-ascorbic acid, preventing attribution.
  7. Long-term controlled trials (beyond 12 weeks) examining peptide anti-aging benefits, skin histology changes, or durability of effect after discontinuation have not been published.
  8. The optimal concentration, application frequency, and formulation vehicle for achieving any dermal bioavailability are not established for any cosmetic peptide class through independent study.

10 / What people say

What formulators and users say

What works

  • Common Signal peptides like palmitoyl pentapeptide-4 (Matrixyl) have genuine RCT support — a 12-week double-blind split-face trial found significant wrinkle improvement at just 3 ppm versus vehicle 112
    well tolerated by the skin and provided significant improvement vs. placebo control for reduction in wrinkles/fine lines Study
  • Common Argireline (acetyl hexapeptide-8) showed up to 30% periorbital wrinkle depth reduction in published studies — its SNARE-inhibiting mechanism is mechanistically sound 211
    skin topography analysis of an oil/water emulsion containing 10% of the hexapeptide on healthy women volunteers reduced wrinkle depth up to 30% upon 30 days treatment Study
  • Common GHK-Cu (copper tripeptide-1) stimulates fibroblast collagen synthesis at picomolar concentrations and has the longest research history of any cosmetic peptide 510
    stimulates collagen synthesis by fibroblasts in culture, with activity detectable between 10⁻¹² and 10⁻¹¹ M and independent of cell number changes Study
  • Common Peptides are exceptionally well-tolerated — no photosensitivity, no purging, no significant irritation risk; safe across skin types including sensitive skin 78
    Peptides appear to be safe, non-invasive anti-aging agents, though larger RCTs with standardized outcomes and histopathologic assessment are warranted Study
  • Common Peptides penetrate the outer skin layer and act as messenger signals rather than sitting inert on the surface — more bioactive than simple film-formers or moisturizers 93
    Peptides can penetrate the outer layer of the skin, so instead of sitting on top of the skin, they sink in more deeply Editorial

What to know

  • Common The penetration problem is real and unresolved — most cosmetic peptides are large hydrophilic molecules above the 500 Da passive-permeation threshold; evidence that intact peptide reaches dermal fibroblasts after cosmetic application is limited 46
    pal-KTTKS had greater stability and permeability than that of un-modified KTTKS Study
  • Common The clinical evidence base is thin and largely industry-affiliated — most pivotal studies were conducted by the peptide's inventor or manufacturer; independent academic replication is scarce 38
    signal peptides, enzyme-inhibitor peptides, neurotransmitter-inhibitor peptides and carrier peptides review
  • Common Peptides are less scientifically validated than retinol or AHAs for anti-aging — research is still developing compared to gold-standard actives 97
    other ingredients like AHAs and retinol are currently more scientifically backed pro-aging ingredients Editorial
  • Some GHK-Cu collagen evidence is almost entirely from cell culture and animal models — controlled human topical RCT data on cosmetic concentrations is extremely limited 105
    most studies done on copper-tripeptide are in-vitro (meaning in the lab and not on real people) or on animals Editorial
  • Some Most clinical peptide studies use multi-ingredient formulations — it is rarely possible to attribute observed improvement to the peptide alone rather than to moisturisation or other actives in the base 81
    only five peptides present evidence supporting their use in sensitive skin, with only one clinical study including volunteers having this condition Study

What you'd only know from the reviews

  • The argireline 'Botox in a bottle' claim requires the peptide to cross the skin, travel to a neuromuscular junction, and competitively inhibit SNARE complex formation in sufficient quantity to reduce muscle contraction. The 2025 permeability review confirms AH-8 faces fundamental delivery barriers; how much reaches neuromuscular junctions after cosmetic topical application has never been directly measured. The 30% wrinkle reduction figure comes from the peptide's inventors applying a 10% concentration — far higher than most consumer products. 62

  • Palmitoylation of KTTKS (creating pal-KTTKS / Matrixyl) is specifically designed to solve the penetration problem by adding a fatty acid tail that increases lipophilicity — this is why signal peptides are palmitoylated, and it is the one formulation-chemistry lever that genuinely improves stratum corneum traversal for this class. Unmodified KTTKS showed far worse penetration than the palmitoylated form in ex-vivo models. 412

  • A 2026 systematic review and meta-analysis of 19 RCTs found that ORAL collagen peptides showed a stronger benefit signal than topical peptides for skin aging outcomes. The topical peptide evidence is weaker by comparison — a nuance rarely surfaced in skincare editorial, where the peptide category is almost exclusively discussed in the context of serums and creams. 7

  • Peptide marketing routinely uses 'clinically tested' language that has no regulated meaning — it can describe an in-house perception survey, a single-arm before/after photo study, or a supplier-conducted in-vitro experiment. For the entire cosmetic peptide class, only a handful of studies meet the minimum threshold of randomised, blinded, vehicle-controlled human trials. 83

  1. 1 Study Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin — Robinson et al. 2005
  2. 2 Study A synthetic hexapeptide (Argireline) with antiwrinkle activity — Blanes-Mira et al. 2002
  3. 3 review Role of topical peptides in preventing or treating aged skin — Gorouhi and Maibach 2009
  4. 4 Study Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS) — Choi et al. 2014
  5. 5 Study Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex GHK-Cu2+ — Maquart et al. 1988
  6. 6 review Acetyl Hexapeptide-8 in Cosmeceuticals — A Review of Skin Permeability and Efficacy — Zdrada-Nowak et al. 2025
  7. 7 Study Oral and topical peptides for skin aging: systematic review and meta-analysis of RCTs — Nukaly et al. 2026
  8. 8 Study Usage of Synthetic Peptides in Cosmetics for Sensitive Skin — Resende et al. 2021
  9. 9 Editorial Peptides for Skin: Benefits, Side Effects, and More — Healthline 2024
  10. 10 Editorial Copper Tripeptide-1 (GHK-Cu) ingredient analysis — INCIDecoder 2024
  11. 11 Editorial Acetyl Hexapeptide-8 (Argireline) ingredient analysis — INCIDecoder 2024
  12. 12 Editorial Palmitoyl Pentapeptide-4 (Matrixyl) ingredient analysis — INCIDecoder 2024

11 / Questions

Frequently asked

Do peptides actually work in skincare, or is it marketing?
The honest answer sits between those poles. The mechanism is real: some peptides genuinely stimulate collagen synthesis in fibroblast cultures (GHK-Cu, PMID:3169264) or signal extracellular matrix remodelling (pal-KTTKS, PMID:18492182). The problem is translation: most cosmetic peptides are large, hydrophilic molecules that face significant obstacles crossing the stratum corneum (PMID:10839713; PMID:25143811), and the independent human clinical trial base is thin. The best-evidenced peptide — palmitoyl pentapeptide-4 — has one genuine split-face RCT showing modest improvement (PMID:18492182), and that study was conducted by the ingredient's manufacturer. Effect sizes across the literature are modest and often rely on industry-sponsored, unblinded, or small-n studies. Peptides are not fraudulent, but their actual in-skin bioavailability after cosmetic application is poorly established, and claims often substantially outrun the evidence. 1456
What is the difference between Matrixyl, Matrixyl 3000, and Matrixyl Synthe'6?
All three are Sederma trade names for palmitoylated signal peptide complexes. Matrixyl is palmitoyl pentapeptide-4 (pal-KTTKS) alone — the original and best-studied. Matrixyl 3000 pairs palmitoyl tripeptide-1 (pal-GHK) with palmitoyl tetrapeptide-7 (pal-GQPR), claiming synergistic ECM stimulation. Matrixyl Synthe'6 is palmitoyl tripeptide-38, claimed to target six ECM components. Each generation has primarily manufacturer-sponsored in-vitro support, with clinical data that is sparse, often multi-ingredient, or not independently replicated. There are no published peer-reviewed head-to-head trials between these three. 18
Is argireline really like Botox?
It mimics the same general category of mechanism — interference with SNARE-mediated neurotransmitter release — but with dramatically lower potency and delivery. Botulinum toxin is injected directly into the target muscle and acts intracellularly with extreme potency. Argireline must cross the skin barrier (problematic for a hydrophilic hexapeptide) and reach neuromuscular junctions in concentrations sufficient to compete meaningfully with endogenous SNAP-25. Published clinical studies show modest periorbital wrinkle reduction at high cosmetic concentrations (10%), but the degree of actual neuromuscular inhibition achievable topically has not been directly measured. Calling it 'Botox in a bottle' is not supported by current evidence. 2310
Why can't I just look at 'clinically tested' peptide claims on product labels?
Because 'clinically tested' is not a regulated phrase. It can mean an in-house consumer-perception survey, a single-arm before/after study with no control group, a study conducted by the ingredient supplier, or a genuine independent RCT — and the first three are overwhelmingly more common in the peptide space. The Robinson 2005 RCT (PMID:18492182) is the closest to rigorous design and it involved only 93 subjects over 12 weeks. The systematic review of oral and topical peptides (PMID:41924746) found that the topical peptide evidence base is modest compared to oral collagen, and most benefit signals in the pooled data were driven by oral formulations. 111
Can I use peptides with vitamin C, retinol, or AHAs?
Peptides are generally compatible with vitamin C formulations in terms of stability; there is no known reactive incompatibility. Some formulators caution that very low pH (below 3.5, as used with L-ascorbic acid) may hydrolyse certain peptide bonds over time, so layering an L-ascorbic acid serum under a separate peptide product is more conservative than combining them. Peptides and retinol are often marketed together. Strong AHAs (low-pH glycolic acid) could in principle degrade peptides on the skin surface, but this has not been studied quantitatively. Peptides are well tolerated and have no known sensitisation concerns (DOI:10.1177/1091581818807863). 12
What peptide class has the most human evidence?
Signal peptides — specifically palmitoyl pentapeptide-4 — have the most published human clinical data, though the dataset is small. The Gorouhi & Maibach 2009 review (PMID:19570099) identified signal peptides as having the strongest clinical evidence of the four peptide classes in cosmetics at the time of publication, with palmitoyl pentapeptide-4 and copper tripeptide-1 as the most studied. The evidence picture has not dramatically changed since then. 71

→ / Related

More from the verified record

12 / References

Sources

12 references · verified 2026-06-13
  1. 1

    Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin

    Robinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL · International Journal of Cosmetic Science 27(3):155-160 · 2005

  2. 2

    A synthetic hexapeptide (Argireline) with antiwrinkle activity

    Blanes-Mira C, Clemente J, Jodas G, Gil A, Fernandez-Ballester G, Ponsati B, Gutierrez L, Perez-Paya E, Ferrer-Montiel A · International Journal of Cosmetic Science 24(5):303-310 · 2002

  3. 3

    The anti wrinkle efficacy of synthetic hexapeptide (Argireline) in Chinese subjects

    Wang Y, Wang M, Xiao XS, Pan P, Li P, Huo J · Journal of Cosmetic and Laser Therapy 15(4):200-205 · 2013

  4. 4

    Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+

    Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP · FEBS Letters 238(2):343-346 · 1988

  5. 5

    The 500 Dalton rule for the skin penetration of chemical compounds and drugs

    Bos JD, Meinardi MM · Experimental Dermatology 9(3):165-169 · 2000

  6. 6

    Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS)

    Choi SY, Kim S, Shin JM, Kim Y, Kim BJ, Kwon SR, Kim J, Kim HS · Biomolecules and Therapeutics (Seoul) 22(5):428-433 · 2014

  7. 7

    Role of topical peptides in preventing or treating aged skin

    Gorouhi F, Maibach HI · International Journal of Cosmetic Science 31(5):327-345 · 2009

  8. 8

    A serum containing vitamins C and E and a matrix-repair tripeptide reduces facial signs of aging as evidenced by Primos analysis and frequently repeated auto-perception

    Lintner K, Gerstein F, Solish N · Journal of Cosmetic Dermatology 19(12):3262-3269 · 2020

  9. 9

    Usage of Synthetic Peptides in Cosmetics for Sensitive Skin

    Resende DISP, Ferreira MS, Sousa-Lobo JM, Sousa E, Almeida IF · Pharmaceuticals 14(8):702 · 2021

  10. 10

    Acetyl Hexapeptide-8 in Cosmeceuticals — A Review of Skin Permeability and Efficacy

    Zdrada-Nowak J, Surgiel-Gemza A, Szatkowska M · International Journal of Molecular Sciences 26(12):5722 · 2025

  11. 11

    Oral and topical peptides for skin aging: systematic review and meta-analysis of randomized controlled trials

    Nukaly A, Halawani K, Irtaza U, Serafi A, Alhawsawi A, Bogari A, Ahmed M, Alturkistani H, Alhaddad A, Shadid M, Alharithy R, Jfri A · Frontiers in Medicine · 2026

  12. 12

    Safety Assessment of Tripeptide-1, Hexapeptide-12, Their Metal Salts and Fatty Acyl Derivatives, and Palmitoyl Tetrapeptide-7 as Used in Cosmetics

    Johnson W, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG, Shank RC, Slaga TJ, Snyder PW, Gill LJ, Heldreth B · International Journal of Toxicology 37(3 suppl):90S-102S · 2018